A Study of CT-868 in Type 1 Diabetes Mellitus
Public ClinicalTrials.gov record NCT06062069. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.
Study identification
- NCT ID
- NCT06062069
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Interventions
- CT-868 Drug
- CT-868 Pen Injector Device
- CT-868 Pen Injector, Placebo Drug
Drug · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2023 (Actual)
- Primary completion
- Jul 7, 2025 (Actual)
- Completion
- Jul 7, 2025 (Actual)
- Last update posted
- Oct 28, 2026
2023 – 2025
United States locations
- U.S. sites
- 22
- U.S. states
- 11
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| John Muir Physician Network Clinical Research Center | Concord | California | 94520 | — |
| Headlands Research- AMCR | Escondido | California | 92025 | — |
| University of Colorado - Barbara Davis Center for Diabetes | Aurora | Colorado | 80045 | — |
| Denver Endocrinology Diabetes and Thyroid Center | Englewood | Colorado | 80113 | — |
| Advent Health | Orlando | Florida | 32804 | — |
| Orlando Health Science Clinic, LLC | Orlando | Florida | 32822 | — |
| Innovative Research Institute | Port Charlotte | Florida | 33952 | — |
| Atlanta Diabetes Associates | Atlanta | Georgia | 30309 | — |
| Rocky Mountain Clinical Research, LLC- Idaho Falls, Idaho | Idaho Falls | Idaho | 83404 | — |
| Iowa Diabetes and Endocrinology Research Center | West Des Moines | Iowa | 50266 | — |
| MedStar Health Research Institute - Washington Hospital Center | Hyattsville | Maryland | 20782 | — |
| University of North Carolina Health Sciences at MAHEC | Asheville | North Carolina | 28803 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27517 | — |
| Lucas Research, Inc | Morehead City | North Carolina | 28557 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Texas Diabetes and Endocrinology, P.A | Austin | Texas | 78731 | — |
| Velocity Clinical Research - Dallas | Dallas | Texas | 75230 | — |
| Research Institute of Dallas | Dallas | Texas | 75231 | — |
| Diabetes & Glandular Disease Clinic, P.A. | San Antonio | Texas | 78229 | — |
| Consano Clinical Research | Shavano Park | Texas | 78231 | — |
| Texas Valley Clinical Research, LLC | Weslaco | Texas | 78596 | — |
| Rainier Clinical Research Center | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06062069, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2026 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06062069 live on ClinicalTrials.gov.